# Cannabis and Antibiotic Resistance: What Cannabigerol Actually Does to MRSA, and What It Does Not Do in People > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-antibiotic-resistance-what-the-evidence-shows/ > **Published:** 2026-09-04T22:51:51-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:40:11-04:00 > **Clinical Summary:** Cannabis and antibiotic resistance: cannabigerol kills MRSA in the lab and in mice. No human trial shows cannabis treats any infection. Here is the line. --- CED Clinical Relevance #61Moderate Clinical RelevancePatients read headlines about cannabis killing superbugs and ask whether CBD can replace an antibiotic. The laboratory data are genuinely interesting and the clinical answer is no. Clinicians need both halves of that sentence ready. Cannabinoids kill drug-resistant bacteria in a test tube at concentrations that would impress any medicinal chemist. That finding is real, reproducible, and about two decades old. What has not happened in those two decades is a single human trial showing that cannabis, CBD, or any cannabinoid treats a bacterial infection. Clinical Insight | CED Clinic Five major phytocannabinoids show potent activity against methicillin-resistant *Staphylococcus aureus* in vitro, with minimum inhibitory concentrations in the low single digits of micrograms per milliliter. Cannabigerol, a compound with no intoxicating effect, is among the most active and works by disrupting the bacterial cytoplasmic membrane. None of that has been translated into a treatment. A 2022 review of the field concluded plainly that the clinical promise of cannabis-derived antimicrobials remains unrealized. The gap between a petri dish and a patient with a bloodstream infection is the entire story here. Antimicrobial ResistanceCannabigerolPreclinical EvidenceInfection SafetyDrug Discovery AudiencePatients, caregivers, and cliniciansPrimary TopicCannabinoid antibacterial activity and its distance from clinical useSource[Read the full source](https://doi.org/10.1021/acsinfecdis.9b00419) Why This Matters Antimicrobial resistance is one of the few medical problems where the pipeline is genuinely thin, and any credible new chemical scaffold deserves attention. Cannabinoids qualify as a credible scaffold. They also happen to be sold on every corner in forms that nobody should mistake for an antibiotic. That combination creates a specific clinical hazard. A patient with a spreading skin infection who delays care because a CBD product is marketed as antibacterial is at risk of a bad outcome from a treatable problem. The honest version of this science protects that patient and still respects the chemistry. What the Laboratory Data Actually Show The modern line of work starts with a 2008 structure-activity study in the *Journal of Natural Products* by Giovanni Appendino, Simon Gibbons, and colleagues. They tested the five major cannabinoids, cannabidiol, cannabichromene, cannabigerol, delta-9-tetrahydrocannabinol, and cannabinol, against a panel of clinically relevant MRSA strains. Every one of them showed potent activity. The effect tolerated substantial changes to the prenyl group but was destroyed by methylation or acetylation of the phenolic hydroxyls, which told the authors that the free phenols carry the pharmacophore. A 2020 paper in *ACS Infectious Diseases* from Eric Brown’s group at McMaster University pushed the work further. Maya Farha and colleagues confirmed activity against MRSA, showed that cannabinoids block biofilm formation, eradicate preformed biofilms, and kill stationary-phase persister cells that ordinary antibiotics leave behind. They identified the cytoplasmic membrane of Gram-positive organisms as cannabigerol’s target, demonstrated efficacy in a mouse systemic MRSA infection model, and showed that cannabinoids act synergistically with polymyxin B against multidrug-resistant Gram-negative pathogens whose outer membrane has been permeabilized. A 2021 paper in *Communications Biology* from Mark Blaskovich’s group at the University of Queensland extended the pathogen list to highly resistant *Staphylococcus aureus*, *Streptococcus pneumoniae*, and *Clostridioides difficile*. It reported excellent antibiofilm activity, topical efficacy in an animal model, membrane disruption as the primary mechanism, and one genuinely novel result: cannabidiol selectively kills a narrow subset of Gram-negative organisms including *Neisseria gonorrhoeae*, which sits on the urgent threat list. The Numbers, and Why Micrograms Per Milliliter Matter A 2024 systematic review in *Antibiotics* by Dhakshila Niyangoda and colleagues screened 3,510 records and included 24 studies reporting minimum inhibitory concentrations for cannabinoids against staphylococci and streptococci. Cannabidiol was the most consistently active compound, with MICs from 0.65 to 32 mg/L against *Staphylococcus aureus* broadly, 0.5 to 4 mg/L against MRSA, and 1 to 2 mg/L against vancomycin-resistant strains. Cannabichromene, cannabigerol, and delta-9-THC also showed meaningful antistaphylococcal activity. Those are respectable numbers. For comparison, many approved antibiotics have MICs in the same range against the same organisms. This is why the field takes cannabinoids seriously as a chemical starting point rather than dismissing them as folk pharmacology. The catch is that an MIC describes a concentration at a bacterium in a controlled broth. It says nothing about whether that concentration can be achieved at the site of an infection in a living person who swallowed a capsule, and nothing about what the same concentration does to human tissue. Those are separate questions, and they are the questions that decide whether a compound becomes a drug. Where the Translation Breaks Down The in vivo work that exists is narrow and specific. Farha and colleagues showed cannabigerol efficacy in a murine systemic MRSA model. Blaskovich and colleagues showed topical efficacy in animals. Those are two demonstrations in rodents. They are not the same as a controlled trial in humans with a defined infection and a clinically meaningful endpoint. A 2022 review in *Biomedicines* by HeeJue Hong, David Scott, and colleagues surveyed the whole landscape of cannabis-derived antimicrobials and reached a blunt conclusion: the clinical promise of these compounds remains unrealized. The same review raised a point that gets almost no attention outside microbiology, which is that a compound with broad antibacterial activity taken chronically may perturb the human microbiome in ways nobody has characterized. That concern applies to long-term cannabinoid therapeutics generally, not only to anyone trying to use them as an antibiotic. There is also no reason to think the cannabinoid content of a consumer product corresponds to an antibacterial dose at a site of infection. A CBD tincture, a gummy, or a topical salve was formulated for a different purpose entirely, and its label tells you nothing about tissue concentrations. Resistance, Biofilms, and the Parts That Look Promising Two findings in this literature are worth keeping, because they address the specific failure modes that make resistant infections hard to treat. The first is biofilm activity. Biofilms shelter bacteria from both antibiotics and the immune system, and they are a major reason device-associated and chronic wound infections recur. A 2025 study in the *Journal of Applied Microbiology* by Pancy Kwong and colleagues tested all five major phytocannabinoids against MRSA biofilms and found minimum inhibitory concentrations between 1 and 2 micrograms per milliliter. Cannabinol was the most potent antibiofilm agent in their assays and induced the highest intracellular reactive oxygen species. Cannabidiol was the least effective against biofilm in most assays while causing the most membrane damage, which suggests these structurally similar molecules are not interchangeable. The second is the resistance question itself. Blaskovich and colleagues reported that cannabidiol showed little propensity to induce resistance on serial passage. If that holds under harder testing, it is a meaningful property, because the rate at which bacteria learn to evade a new agent largely determines how long that agent stays useful. A 2026 paper in *ACS Omega* from Shanteri Singh’s group at the University of Oklahoma synthesized 26 cannabigerol and cannabigerolic acid derivatives and found that terpene chain lengths between 6 and 13 carbons produced potent activity against Gram-positive strains including MRSA and vancomycin-resistant *Enterococcus*, with no detectable cytotoxicity toward mammalian cells and several analogs reaching MICs comparable to daptomycin. That is what a real drug discovery program looks like: not the plant, but a series built from it. What This Means in a Clinic Room Cannabis does not treat infection. There is no clinical evidence to support using any cannabis product in place of, or in addition to, an antibiotic for a suspected or confirmed bacterial infection. A patient who asks whether their CBD oil will help a cellulitis should hear a clear no, followed by an appointment. The practical risk is delay. Skin and soft tissue infections, dental infections, and urinary infections are ordinary problems with ordinary treatments, and they become serious problems when treatment is postponed. Marketing language borrowed from preclinical microbiology has a real capacity to cause that delay. Two smaller points belong in the same conversation. Patients on immunosuppression or with indwelling hardware should be told directly that self-treating an infection with any supplement is unsafe. And anyone taking high-dose cannabidiol chronically should know that its antibacterial properties, whatever they eventually mean clinically, have not been evaluated for effects on their own gut flora. Evidence SnapshotEvidence ClassPreclinical: in vitro susceptibility testing, biofilm assays, and rodent infection models. No human trials.Foundational SAR StudyAppendino G, Gibbons S, et al. Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. J Nat Prod. 2008;71(8):1427-30. PMID 18681481Mechanism and In Vivo ModelFarha MA, El-Halfawy OM, Brown ED, et al. Uncovering the Hidden Antibiotic Potential of Cannabis. ACS Infect Dis. 2020;6(3):338-346. PMID 32017534Gram-Negative FindingBlaskovich MAT, Kavanagh AM, et al. The antimicrobial potential of cannabidiol. Commun Biol. 2021;4(1):7. PMID 33469147Systematic ReviewNiyangoda D, Thomas J, et al. Antibiotics (Basel). 2024;13(11):1023. 24 studies from 3,510 screened records. PMID 39596719Reported MIC RangeCannabidiol 0.5 to 4 mg/L against MRSA; 1 to 2 mg/L against vancomycin-resistant S. aureus; 0.65 to 32 mg/L against S. aureus overallBiofilm DataKwong PTH, Kwok PCL, et al. J Appl Microbiol. 2025;136(9):lxaf214. All five major phytocannabinoids MIC 1 to 2 ug/mL; cannabinol most potent antibiofilm. PMID 40844832Analog ProgramMandal PS, Singh S, et al. ACS Omega. 2026;11(11):18345-18355. 26 CBG and CBGA derivatives; several MICs comparable to daptomycin. PMID 41908444Field AssessmentHong H, Saxena D, Scott DA, et al. Biomedicines. 2022;10(8):1959: clinical promise of cannabis-derived antimicrobials remains unrealized. PMID 36009504Human Efficacy DataNone. No randomized controlled trial has tested a cannabinoid as treatment for a bacterial infection in humans.PMID / DOI (primary source)32017534 / 10.1021/acsinfecdis.9b00419 How Strong Is This Evidence? As preclinical microbiology, this body of work is strong. Activity has been reproduced across independent laboratories on three continents over eighteen years, with consistent structure-activity relationships, a defined mechanism, quantified minimum inhibitory concentrations, biofilm and persister-cell data, and animal models. That is more than most natural product leads ever accumulate. As clinical evidence, it is nonexistent. Every claim above describes bacteria in controlled conditions or rodents with experimentally induced infections. The translation from a reproducible MIC to a treatment that helps a person has failed for a very large number of compounds with data this good, and there is no trial here to say cannabinoids are different. Where This Paper Deserves Skepticism In vitro potency against Gram-positive organisms is a crowded space. Many plant phenols inhibit staphylococci in broth, and most do so through nonspecific membrane effects that do not survive contact with serum proteins, host tissue, or the pharmacokinetics of an actual dose. Membrane disruption, the mechanism identified for both cannabigerol and cannabidiol, is exactly the mechanism most likely to behave this way. The Gram-negative results deserve a careful read. Farha and colleagues reported cannabinoid activity against Gram-negative organisms whose outer membrane had been chemically permeabilized, which is a laboratory manipulation rather than a clinical scenario, and synergy with polymyxin B, which means the cannabinoid is a partner rather than the agent. The unassisted Gram-negative activity Blaskovich and colleagues found is restricted to a narrow subset of species. Almost none of this work used commercial cannabis products. It used purified or synthesized single compounds at known concentrations. Nothing about it validates a marketed CBD oil, tincture, salve, or flower. What This Paper Does Not Show This literature does not show that cannabis treats any infection in humans. It does not establish a dose, a route, a duration, or a safety profile for antibacterial use. It does not show that oral or inhaled cannabinoid products reach antibacterial concentrations anywhere in the body. It does not show benefit as an adjunct to standard antibiotics in people. It also does not resolve the other direction of the question. Whether chronic cannabinoid exposure meaningfully alters the human microbiome or contributes to selection pressure for resistance has been raised as a plausible concern in review but has not been measured in a way that answers it. How This Fits With the Broader Clinical Conversation The useful frame here is drug discovery, not herbal medicine. The 2026 analog work out of the University of Oklahoma is the honest continuation of this line: take the scaffold, vary the terpene chain, measure potency and mammalian cytotoxicity separately, and build toward a candidate. That is how a natural product becomes a medicine, and it takes years more work after the point this field has reached. There is a parallel worth noting. Cannabidiol reached the clinic for epilepsy through exactly this route, as a purified pharmaceutical compound tested in randomized trials at defined doses, not as a botanical preparation. If a cannabinoid antibiotic ever arrives, it will arrive the same way, probably as a topical agent or a decolonization strategy first, and it will not look like anything currently on a dispensary shelf. Dr. Caplan’s Take The chemistry here is legitimately good, and I say that as someone who spends a fair amount of time telling patients that a promising cannabis headline does not mean what they think it means. Cannabigerol killing MRSA persister cells and clearing established biofilms is not a small result. If it were a synthetic compound from a pharmaceutical library, it would have a development program. What I will not do is let that interest blur the clinical line. A patient with a red, warm, expanding area on their leg needs an antibiotic and an examination, not a tincture. I have seen what a few days of delay does to a soft tissue infection, and no laboratory finding is worth that. The right thing to say is that this science is real, it is early, and it has nothing to offer your infection today. Clinical Bottom Line Cannabinoids, particularly cannabigerol and cannabidiol, have reproducible antibacterial activity against drug-resistant Gram-positive organisms in laboratory conditions, with defined mechanisms and supportive rodent data. No human trial has tested them as treatment for infection, and no cannabis product should be used in place of an antibiotic. Treat this as a drug discovery lead, and treat infections with antibiotics. What a Careful Reader Should Take Away The finding worth carrying forward is that the cannabinoid scaffold has real, mechanistically characterized antibacterial activity and a promising resistance profile, which makes it a reasonable starting point for medicinal chemistry. The finding not to carry forward is any version of the sentence cannabis fights superbugs, applied to a person, a product, or an infection. Evidence Interpretation Guide Table of Contents - [How to read a preclinical antimicrobial result without over-reading it](#How_to_read_a_preclinical_antimicrobial_result_without_over-reading_it) - [Cannabis and Antimicrobial Resistance, Seen From Eight Angles](#Cannabis_and_Antimicrobial_Resistance_Seen_From_Eight_Angles)[This does not change what you should do about an infection](#This_does_not_change_what_you_should_do_about_an_infection) - [Have the short version ready](#Have_the_short_version_ready) - [Membrane-active phenols are a well-worn dead end](#Membrane-active_phenols_are_a_well-worn_dead_end) - [Read the Gram-negative claims narrowly](#Read_the_Gram-negative_claims_narrowly) - [This is an old observation with a new mechanism](#This_is_an_old_observation_with_a_new_mechanism) - [Nothing here belongs in self-care](#Nothing_here_belongs_in_self-care) - [Watch the analogs, not the plant](#Watch_the_analogs_not_the_plant) - [Marketing is running ahead of the evidence](#Marketing_is_running_ahead_of_the_evidence) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to read a preclinical antimicrobial result without over-reading it The Research QuestionDo cannabinoids inhibit or kill antibiotic-resistant bacteria, by what mechanism, and at what concentrations?The Patient QuestionI saw that cannabis kills MRSA. Can I use CBD for this infection instead of taking the antibiotic?The Bottom LineCannabinoids inhibit resistant Gram-positive bacteria at low micrograms per milliliter and disrupt biofilms. That is a laboratory fact. It is not a treatment, and no trial has tested it in people. CED Perspective Lens ## Cannabis and Antimicrobial Resistance, Seen From Eight Angles One body of preclinical evidence, read through the lenses that matter in clinical practice. Lens OverviewPhytocannabinoids inhibit MRSA and other resistant Gram-positive bacteria in vitro at low concentrations, disrupt biofilms, and work in rodent models. No human trial has tested them as a treatment for infection. #### This does not change what you should do about an infection If you have an infection, you need an evaluation and, when indicated, an antibiotic. Nothing in this research supports using a CBD product, hemp oil, or cannabis flower to treat one. The concentrations that killed bacteria in these studies were purified compounds applied directly to bacteria in a laboratory. The most common way this science causes harm is not through a side effect. It is through delay, when someone waits a few days to see whether a topical product helps before calling a clinician. Lens takeawayInteresting chemistry, zero clinical application. Call about the infection. #### Have the short version ready Patients bring this up, usually after a headline. The efficient answer has three parts: yes, the laboratory data are real and reproducible; no, there are no human trials; and no, a marketed product is not the compound that was tested. It is also worth asking directly whether a patient has been self-treating anything infectious, particularly in diabetes, immunosuppression, or with indwelling hardware, where the cost of delay is highest. Lens takeawayAffirm the science, close the clinical door, then screen for delayed presentations. #### Membrane-active phenols are a well-worn dead end A great many plant phenolics inhibit Gram-positive bacteria in broth by perturbing the membrane, and the attrition rate from that starting point to an approved drug is close to total. Serum protein binding, tissue distribution, and mammalian membrane toxicity kill most of them. The eighteen years between Appendino’s structure-activity paper and the present without a clinical candidate is itself informative. Reproducible in vitro potency has not been the rate-limiting step. Lens takeawayPotency in broth is the easy part; the field has not cleared the hard part. #### Read the Gram-negative claims narrowly Cannabinoid activity against Gram-negative organisms in the McMaster work required either chemical permeabilization of the outer membrane or partnership with polymyxin B. Both are legitimate experimental findings and neither describes a standalone agent. The unassisted activity against *Neisseria gonorrhoeae* reported from Queensland is the more striking result and applies to a narrow subset of species, not to Gram-negatives as a class. Lens takeawayThe Gram-negative story is a synergy story plus one interesting exception. #### This is an old observation with a new mechanism Antibacterial properties of cannabis were described in the mid twentieth century, long before the endocannabinoid system was known, and the observation sat largely unexamined for decades. Appendino’s 2008 structure-activity work is what converted an anecdote into a pharmacophore. The 2020 McMaster paper added what had been missing, which was a defined molecular target and a demonstration that the effect survives in a living animal. Lens takeawayThe claim is old; the mechanism and the animal data are recent. #### Nothing here belongs in self-care There is no product, dose, route, or protocol supported by this evidence. Cannabinoid content on a consumer label was determined for a different purpose and bears no relationship to a concentration at a site of infection. For a wound, an abscess, a dental infection, or a urinary infection, the practical step is an evaluation. That remains true regardless of how the laboratory data look. Lens takeawayNo product, no dose, no protocol. Get the infection looked at. #### Watch the analogs, not the plant The productive direction is synthetic modification of the cannabigerol scaffold with separate measurement of antibacterial potency and mammalian cytotoxicity, which is what the 2026 Oklahoma work did. Several analogs reached minimum inhibitory concentrations comparable to daptomycin without detectable cytotoxicity in their assays. A plausible first clinical application is topical or decolonization rather than systemic therapy, because that is where the pharmacokinetic obstacle is smallest. Lens takeawayIf this becomes a drug it will be a synthetic analog used topically, not a botanical. #### Marketing is running ahead of the evidence Products are already marketed with antibacterial language drawn from this preclinical literature. That language is not supported for human use, and in the context of infection it carries a specific risk of delayed care. Antimicrobial stewardship arguments cut both ways here. The pipeline needs new scaffolds, and it also needs the public not to substitute unproven products for effective ones. Lens takeawaySupport the research, scrutinize the marketing. Related Reading at CED ClinicContinue exploring the evidence[Exploring the Antibacterial Potential of Cannabinoids Against MRSA](https://cedclinic.com/cannabinoids-against-mrsa-antibacterial-potential/) A closer look at the specific MRSA susceptibility data behind these headlines. [Read the MRSA evidence](https://cedclinic.com/cannabinoids-against-mrsa-antibacterial-potential/)[Can Medicinal Plants Help Fight Antibiotic-Resistant Infections?](https://cedclinic.com/medicinal-plants-antibacterial-wound-healing/) The wider botanical antibacterial literature, and why so little of it reaches the clinic. [See the broader review](https://cedclinic.com/medicinal-plants-antibacterial-wound-healing/)[Cannabis Compounds Show Potential as Natural Antifungal Agents](https://cedclinic.com/study-finds-cannabis-compounds-show-potential-as-natural-antifungal-agents/) The parallel antifungal literature sits at the same preclinical stage, with the same limits. [Compare the antifungal data](https://cedclinic.com/study-finds-cannabis-compounds-show-potential-as-natural-antifungal-agents/) Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) ## Frequently Asked Questions Can cannabis or CBD treat a bacterial infection? No. There is no clinical evidence that cannabis, CBD, or any cannabinoid treats a bacterial infection in humans. The antibacterial findings come from purified compounds applied directly to bacteria in laboratory conditions and from two rodent studies. If you have a suspected infection, you need a clinical evaluation and, when indicated, an antibiotic. Using a cannabis product instead risks a serious outcome from a treatable problem. Which cannabinoid is most active against MRSA? Cannabigerol and cannabidiol are the most studied. A 2020 study in ACS Infectious Diseases identified cannabigerol as targeting the cytoplasmic membrane of Gram-positive bacteria and showed it eradicated MRSA biofilms and persister cells. A 2024 systematic review in Antibiotics found cannabidiol the most consistently potent across studies, with minimum inhibitory concentrations of 0.5 to 4 mg per liter against MRSA. Cannabichromene, cannabinol, and THC also show activity. Does cannabigerol get you high? Cannabigerol is not intoxicating. It is the non-psychoactive precursor from which the plant synthesizes THC and CBD, and it lacks the strong CB1 receptor activity that produces intoxication. That property is part of why it attracts interest as a drug development scaffold: a compound can be optimized for antibacterial potency without carrying a psychoactive liability into the clinic. What is a minimum inhibitory concentration, and why does it matter here? The minimum inhibitory concentration, or MIC, is the lowest concentration of a compound that stops visible bacterial growth in a controlled broth culture. Cannabinoid MICs against resistant staphylococci fall in the range of many approved antibiotics, which is why the finding is taken seriously. An MIC says nothing about whether that concentration can be reached at an infection site in a person, or what it would do to human tissue. Have cannabinoids been tested against infections in animals? Yes, in two limited settings. Researchers at McMaster University demonstrated cannabigerol efficacy in a mouse model of systemic MRSA infection. A University of Queensland group demonstrated topical efficacy of cannabidiol in an animal skin infection model. Both are legitimate preclinical results. Neither is equivalent to a controlled human trial with a defined infection and a clinically meaningful endpoint, and no such trial has been published. Why do cannabinoids work against biofilms? Biofilms shelter bacteria in a matrix that blocks antibiotics and immune cells, which is why device and chronic wound infections recur. Cannabinoids appear to act on bacterial membranes directly rather than on growth-dependent targets, so they reach cells that are metabolically dormant. A 2025 study in the Journal of Applied Microbiology found all five major phytocannabinoids active against MRSA biofilms, with cannabinol the most potent in those assays. Could using cannabis contribute to antibiotic resistance? That question has been raised but not answered. A 2022 review in Biomedicines noted that compounds with broad antibacterial activity taken chronically could plausibly alter the human microbiome, and argued this should be considered when designing long-term cannabinoid therapeutics. On the other side, cannabidiol showed little tendency to induce resistance during serial laboratory passage. Neither observation has been evaluated in people. What would it take for a cannabinoid antibiotic to reach patients? The same path any drug takes. A 2026 study in ACS Omega synthesized 26 cannabigerol derivatives and measured potency and mammalian cytotoxicity separately, with several analogs reaching MICs comparable to daptomycin. Work of that kind has to be followed by formulation, pharmacokinetic studies, toxicology, and randomized human trials. A realistic first application would likely be topical or decolonization rather than systemic treatment. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).